Meisner D J, Carlson R J, Gottlieb A J
Arch Intern Med. 1985 Apr;145(4):700-2.
Procainamide hydrochloride-induced thrombocytopenia has infrequently been reported in the past. We report six cases of thrombocytopenia following the administration of the sustained-release form of procainamide. Three of these cases had platelet counts of less than 15,000/microL. The mean time to onset of thrombocytopenia from drug administration was 40 days (range, nine to 71 days). The mean time until normalization of the platelet counts after the drug therapy was stopped was 7.8 +/- 3.1 days (range, four to nine days). Oral prednisone therapy had little apparent benefit. The thrombocytopenia was not part of a systemic lupus erythematosus syndrome. We believe that thrombocytopenia is an important side effect of sustained-release procainamide therapy.
过去,盐酸普鲁卡因胺诱发的血小板减少症鲜有报道。我们报告6例服用缓释型普鲁卡因胺后出现血小板减少症的病例。其中3例患者的血小板计数低于15,000/微升。从用药到出现血小板减少症的平均时间为40天(范围为9至71天)。停药后血小板计数恢复正常的平均时间为7.8±3.1天(范围为4至9天)。口服泼尼松治疗几乎没有明显益处。血小板减少症并非系统性红斑狼疮综合征的一部分。我们认为血小板减少症是缓释型普鲁卡因胺治疗的一种重要副作用。